Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.4
4.8
Journals
Biomolecules
Special Issues
Biomarkers Profile and Biomolecular Signaling in Heart Failure and Cardiomyopathies
share announcement

Biomarkers Profile and Biomolecular Signaling in Heart Failure and Cardiomyopathies

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biomarkers".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 14496

Special Issue Editors

Dr. Matteo Beltrami

E-Mail Website
Guest Editor
Cardiology Unit, San Giovanni di Dio Hospital, 50143 Florence, Italy
Interests: heart failure
Dr. Alberto Palazzuoli

E-Mail Website
Guest Editor
Cardiovascular Diseases Unit, Cardio Thoracic and Vascular Department, Le Scotte Hospital, University of Siena, Viale Bracci 14, 53100 Siena, Italy
Interests: heart failure; intensive care medicine

Special Issue Information

Dear Colleagues,

Currently, specific biomarkers with different pathophysiological backgrounds, particularly N-terminal pro b-type natriuretic peptide and high-sensitivity cardiac troponin I, play a key role in diagnosis, treatment, and risk stratification in cardiomyopathies. Elevated biomarkers seem to depict patients with more severe disease, adding diagnostic and prognostic information to conventional assessment such as left ventricular ejection fraction and NYHA class. A multi-biomarker approach for personalized medical care is not too far-fetched, and such an approach can greatly enhance diagnosis, prognostication, and therapy guidance for cardiomyopathies.

The aim of this Special Issue is to offer to readers the best overview of the current state of knowledge of biomolecular biomarkers in cardiomyopathies.

Dr. Matteo Beltrami
Dr. Alberto Palazzuoli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • cardiomyopathies
  • diagnosis
  • prognosis
  • hypertrophic cardiomyopathy
  • dilated cardiomyopathy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 2398 KiB  
Article
Low Valine Serum Levels Predict Increased 1-Year Mortality in Acute Heart Failure Patients
by Iva Klobučar, Luka Vidović, Ilona Arih, Margarete Lechleitner, Gudrun Pregartner, Andrea Berghold, Hansjörg Habisch, Tobias Madl, Saša Frank and Vesna Degoricija
Biomolecules 2023, 13(9), 1323; https://doi.org/10.3390/biom13091323 - 29 Aug 2023
Cited by 2 | Viewed by 1363
Abstract
Considering the relationship between disease severity and the extent of metabolic derangement in heart failure, we hypothesized that the serum levels of metabolites may have prognostic value for 1-year mortality in acute heart failure (AHF). The AHF study was a prospective, observational study [...] Read more.
Considering the relationship between disease severity and the extent of metabolic derangement in heart failure, we hypothesized that the serum levels of metabolites may have prognostic value for 1-year mortality in acute heart failure (AHF). The AHF study was a prospective, observational study enrolling consecutive patients hospitalized due to AHF. Metabolites were measured in serum collected at admission using NMR spectroscopy. Out of 315 AHF patients, 118 (37.5%) died within 1 year after hospitalization for AHF. The serum levels of 8 out of 49 identified metabolites were significantly different between patients who were alive and those who died within 1 year after hospitalization for AHF. Of these, only valine was significantly associated with 1-year mortality (hazard ratio 0.73 per 1 standard deviation increase, 95% confidence interval: 0.59–0.90, p = 0.003) in the multivariable Cox regression analyses. Kaplan–Maier analysis showed significantly higher survival rates in AHF patients with valine levels above the median (>279.2 µmol/L) compared to those with valine levels ≤ 279.2 µmol/L. In a receiver operating characteristics curve analysis, valine was able to discriminate between the two groups with an area under the curve of 0.65 (95% CI 0.59–0.72). We conclude that valine serum levels might be of prognostic value in AHF. Full article
(This article belongs to the Special Issue Biomarkers Profile and Biomolecular Signaling in Heart Failure and Cardiomyopathies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 1675 KiB  
Review
Renal Assessment in Acute Cardiorenal Syndrome
by Piotr Łagosz, Jan Biegus, Szymon Urban and Robert Zymliński
Biomolecules 2023, 13(2), 239; https://doi.org/10.3390/biom13020239 - 27 Jan 2023
Cited by 2 | Viewed by 6420
Abstract
Cardiorenal syndrome (CRS) is a complex, heterogeneous spectrum of symptoms that has kept cardiologists awake for decades. The heart failure (HF) population being burdened with multimorbidity poses diagnostic and therapeutic challenges even for experienced clinicians. Adding deteriorated renal function to the equation, which [...] Read more.
Cardiorenal syndrome (CRS) is a complex, heterogeneous spectrum of symptoms that has kept cardiologists awake for decades. The heart failure (HF) population being burdened with multimorbidity poses diagnostic and therapeutic challenges even for experienced clinicians. Adding deteriorated renal function to the equation, which is one of the strongest predictors of adverse outcome, we measure ourselves against possibly the biggest problem in modern cardiology. With the rapid development of new renal assessment methods, we can treat CRS more effectively than ever. The presented review focuses on explaining the pathophysiology, recent advances and current practices of monitoring renal function in patients with acute CRS. Understanding the dynamic interaction between the heart and the kidney may improve patient care and support the selection of an effective and nephroprotective treatment strategy. Full article
(This article belongs to the Special Issue Biomarkers Profile and Biomolecular Signaling in Heart Failure and Cardiomyopathies)
►▼ Show Figures

Figure 1

16 pages, 985 KiB  
Review
Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature
by Alberto Palazzuoli, Francesco Tramonte and Matteo Beltrami
Biomolecules 2023, 13(1), 173; https://doi.org/10.3390/biom13010173 - 13 Jan 2023
Cited by 5 | Viewed by 3385
Abstract
Heart failure with preserved ejection fraction (HFpEF) remains a poorly characterized syndrome with many unknown aspects related to different patient profiles, various associated risk factors and a wide range of aetiologies. It comprises several pathophysiological pathways, such as endothelial dysfunction, myocardial fibrosis, extracellular [...] Read more.
Heart failure with preserved ejection fraction (HFpEF) remains a poorly characterized syndrome with many unknown aspects related to different patient profiles, various associated risk factors and a wide range of aetiologies. It comprises several pathophysiological pathways, such as endothelial dysfunction, myocardial fibrosis, extracellular matrix deposition and intense inflammatory system activation. Until now, HFpEF has only been described with regard to clinical features and its most commonly associated risk factors, disregarding all biological mechanisms responsible for cardiovascular deteriorations. Recently, innovations in laboratory and metabolomic findings have shown that HFpEF appears to be strictly related to specific cells and molecular mechanisms’ dysregulation. Indeed, some biomarkers are efficient in early identification of these processes, adding new insights into diagnosis and risk stratification. Moreover, recent advances in intermediate metabolites provide relevant information on intrinsic cellular and energetic substrate alterations. Therefore, a systematic combination of clinical imaging and laboratory findings may lead to a ‘precision medicine’ approach providing prognostic and therapeutic advantages. The current review reports traditional and emerging biomarkers in HFpEF and it purposes a new diagnostic approach based on integrative information achieved from risk factor burden, hemodynamic dysfunction and biomarkers’ signature partnership. Full article
(This article belongs to the Special Issue Biomarkers Profile and Biomolecular Signaling in Heart Failure and Cardiomyopathies)
►▼ Show Figures

Figure 1

12 pages, 978 KiB  
Review
Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
by Francesca Romana Prandi, Lucy Barone, Dalgisio Lecis, Martina Belli, Domenico Sergi, Marialucia Milite, Stamatios Lerakis, Francesco Romeo and Francesco Barillà
Biomolecules 2022, 12(10), 1349; https://doi.org/10.3390/biom12101349 - 22 Sep 2022
Cited by 8 | Viewed by 2605
Abstract
Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia and associated with an increased risk of morbidity and mortality, primarily from cardiovascular and renal diseases. Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) are novel drugs for the treatment of type 2 DM and [...] Read more.
Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia and associated with an increased risk of morbidity and mortality, primarily from cardiovascular and renal diseases. Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) are novel drugs for the treatment of type 2 DM and heart failure (HF). SGLT2-Is mediate protective effects on both the renal and cardiovascular systems. This review addresses the current knowledge on the biomolecular mechanisms of the cardiorenal protective effects of SGLT2-Is, which appear to act mainly through non-glucose-mediated pathways. Cardiorenal protection mechanisms lead to reduced chronic renal disease progression and improved myocardial and coronary endothelial function. Concomitantly, it is possible to observe reflected changes in biomarkers linked with diabetic kidney disease and HF. Full article
(This article belongs to the Special Issue Biomarkers Profile and Biomolecular Signaling in Heart Failure and Cardiomyopathies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop